Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03968848 · ClinicalTrials.gov registry record · Phase 1
Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite
A Phase 1 study, sponsored by Acerta Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT03968848 is a Phase 1 study that has completed, run by Acerta Pharma. The registered enrollment target is 16 participants.
The verdict
NCT03968848, a Phase 1 study, has completed, sponsored by Acerta Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study is investigate the influence of severe hepatic impairment on the pharmacokinetics of acalabrutinib and its metabolite.
Interventions
- DRUG acalabrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2018-11-12 |
| Est. Completion | 2019-03-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03968848
The ClinicalTrials.gov registry entry for NCT03968848 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acerta Pharma, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which acalabrutinib is the first listed.
NCT03968848 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03968848 about?
NCT03968848 is a clinical study titled "Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite". This study is investigate the influence of severe hepatic impairment on the pharmacokinetics of acalabrutinib and its metabolite.
What is the current status of trial NCT03968848?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2018-11-12. Estimated completion is 2019-03-29.
What interventions are being tested in trial NCT03968848?
The interventions under investigation include: acalabrutinib (DRUG).
Who is sponsoring clinical trial NCT03968848?
This trial is sponsored by Acerta Pharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.